Wedbush restated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a report issued on Friday morning, Benzinga reports. They currently have a $8.00 price objective on the stock.
ELEV has been the topic of several other reports. JMP Securities restated a market outperform rating and set a $7.00 target price on shares of Elevation Oncology in a research report on Thursday, March 7th. HC Wainwright reiterated a buy rating and issued a $6.00 target price on shares of Elevation Oncology in a report on Tuesday, April 9th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of Buy and a consensus price target of $7.25.
Get Our Latest Stock Analysis on ELEV
Elevation Oncology Price Performance
Elevation Oncology (NASDAQ:ELEV – Get Free Report) last posted its earnings results on Wednesday, March 6th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. On average, equities research analysts forecast that Elevation Oncology will post -0.87 earnings per share for the current fiscal year.
Elevation Oncology Company Profile
Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Recommended Stories
- Five stocks we like better than Elevation Oncology
- Breakout Stocks: What They Are and How to Identify Them
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- The 3 Best Fintech Stocks to Buy Now
- 3 Value Stocks You Can Buy Before They Become Big
- What is Insider Trading? What You Can Learn from Insider Trading
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.